The Hidden Cost of Technical Debt in Medical Device Development
Engineering expertise and regulatory accountability almost never sit in the same person. As of February 2, 2026, FDA’s new inspection framework follows risk across the full product lifecycle—and that gap is no longer a background risk. It is a current exposure.
Simultaneous Challenges, Not Sequential Problem The Operating Reality of a Complex Multi-Program Executive in Medical Device Development
A regulatory attorney session, an international design review, a 483 remediation call, a hospital executive update, a QMS compliance deadline, and a CFO budget meeting—in the same week. Not exceptional. Most weeks. Here’s what actually makes it sustainable.
Own Your Device’s Entire Journey: Why Smart Companies Treat Complaints as Strategic Assets
Complaint handling ranked 3rd in FDA warning letter citations in FY2025. With QMSR now in effect, one complaint can trigger MDR evaluation, CAPA, design reviews, risk updates, and multi-stakeholder notifications. Here’s how to stop firefighting and start leading.